Alexion Pharmaceuticals, Inc. (ALXN) Tops Q1 EPS by 4c; Boosts Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Alexion Pharmaceuticals (ALXN) Fundamentals Strong - Analyst
April 25, 2013 2:07 PM EDTWells Fargo today maintained a Market Perform rating on Alexion Pharmaceuticals (NASDAQ: ALXN). This morning Alexion reported Q1 results.
Commenting on the results, analyst Brian Abrahams said, "Q1 results were mostly inline with our expectation, though the raise in guidance should provide some... More
